KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) EBT Margin (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EBT Margin for 17 consecutive years, with 134.05% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 27021.0% to 134.05% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 38.54% through Dec 2025, up 12981.0% year-over-year, with the annual reading at 38.54% for FY2025, 12981.0% up from the prior year.
  • EBT Margin for Q4 2025 was 134.05% at Bio-Rad Laboratories, up from 66.02% in the prior quarter.
  • The five-year high for EBT Margin was 672.32% in Q3 2021, with the low at 623.92% in Q1 2022.
  • Average EBT Margin over 5 years is 14.13%, with a median of 17.97% recorded in 2025.
  • The sharpest move saw EBT Margin plummeted -80240bps in 2022, then skyrocketed 63644bps in 2023.
  • Over 5 years, EBT Margin stood at 276.63% in 2021, then skyrocketed by 154bps to 149.44% in 2022, then crashed by -58bps to 62.89% in 2023, then plummeted by -317bps to 136.16% in 2024, then soared by 198bps to 134.05% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 134.05%, 66.02%, and 63.54% for Q4 2025, Q3 2025, and Q2 2025 respectively.